May. 9 at 12:29 AM
eXoZymes (Nasdaq:
$EXOZ ) CEO Michael Heltzen frames the company’s platform as a new form of chemistry with applications across nutraceuticals and pharmaceuticals.
eXoZymes Inc. (NASDAQ: EXOZ) CEO Michael Heltzen appeared on The Upside to discuss the company’s cell-free biomanufacturing platform, its focus on NCT, and the broader opportunity to apply AI-engineered enzymes outside the cell.
Watch the clip here:https://youtube.com/shorts/KHARx1GscpQ?feature=share
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1.
Asked about eXoZymes’ growth potential, Heltzen says the company is “here to make it really, really large” and describes the platform as “a new form of chemistry.”
In the full interview, Heltzen discusses NCT, a naturally occurring molecule found in black pepper, and explains how eXoZymes’ platform is designed to produce compounds at scale. He also describes the company’s dual-track opportunity: an over-the-counter nutraceutical path for natural NCT and a pharmaceutical path for more potent analogs.
eXoZymes is a Monrovia, California-based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to transform sustainable feedstocks into high-value compounds. The company is currently focused on products including NCT, non-intoxicating cannabinoids, and other applications where its platform may offer advantages in speed, purity, and scalability.
Learn more at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
$DNLI,
$TWST,
$DNA,
$ARKG